Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CERo Therapeutics Holdings, Inc. - Common Stock
(NQ:
CERO
)
0.0951
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CERo Therapeutics Holdings, Inc. - Common Stock
< Previous
1
2
Next >
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
January 07, 2026
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
December 17, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Announces Trading on OTCQB Market
December 02, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
November 05, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
November 04, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Announces Listing on OTC Markets
November 03, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
October 29, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
October 21, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
October 15, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
October 13, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
September 22, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
September 09, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
September 08, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
September 05, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236
July 31, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
June 23, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
Peraso Inc (NASDAQ: PRSO) Deploys Stealth Tech Shipment for Military Use – Tapping $500M NATO Market – More Stocks Inside
June 17, 2025
Via
AB Newswire
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
June 17, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
June 11, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
June 06, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
June 02, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
May 30, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
May 08, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
April 30, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
April 25, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
April 24, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
April 22, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
April 10, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
April 09, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
March 31, 2025
From
CERo Therapeutics Holdings, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
